title: [Radiochemotherapy in anal canal epidermoid cancer].
abstract: Epidermoid anal canal carcinomas are radio- and chemosensitive tumors. Within a few decades, conservative treatment has replaced mutilating surgery as standard therapeutic practice. Exclusive high-dose radiotherapy remains the standard treatment of early stages T1-T2 N0 smaller than 4 cm. Three phase III trials demonstrated the benefits of combined chemotherapy and irradiation on the local efficacy and colostomy-free survival. Mitomycin C and 5 FU were delivered on weeks 1 and 5 of the irradiation. Concomitant 5 FU and CDDP regimen and neoadjuvant chemotherapy were evaluated on phase II trials. Ongoing intensification phase III trials are described.
authors: Centre Alexis-Vautrin, Vandoeuvre-lès-Nancy, France.
authors: D
authors: D
authors: Peiffert
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001005:Anus Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy*; D002294:Carcinoma, Squamous Cell / Q000145:classification / Q000188:drug therapy* / Q000453:epidemiology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D003125:Colostomy; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage; D020360:Neoadjuvant Therapy / Q000379:methods*; D009367:Neoplasm Staging; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D016685:Mitomycin; D002945:Cisplatin; D005472:Fluorouracil